A hot US CPI print set off a repricing of "AI debt" that spread from US neocloud and server stocks to Korea, Hong Kong, China A-shares and crypto. The briefing argues the credit market is punishing leverage without cash flow, not AI demand. TSMC and ASML both said supply is short. Biotech and life-science tools rose in all three equity markets, which supports the briefing's thesis that AI is turning biology from binary bets into platform businesses.
Key signals
- US September CPI came in at 3.7% against 3.6% expected, and PPI at 6.3% against 5.5%. October rate-hike odds briefly neared 50%. CoreWeave's 2031 notes yielded above 16%, and its five-year CDS briefly topped 1,140bp. Oracle's CDS reached 282bp.
- KOSPI fell 7.5% in a circuit-breaker day, its ninth this year. Samsung fell 9% and SK Hynix 11%. The Philadelphia Semiconductor Index (SOX) has fallen seven sessions in a row, down 12.4% from its 10-06 high.
- TSMC reported Q3 revenue of $46.72B against guidance of $44.6–45.8B, with a 66.4% gross margin. Q4 guidance is $52.3–54.3B. ASML said supply for 2027 and 2028 cannot fully meet customer demand under current plans.
- Eli Lilly rose 3.6%. The Hong Kong Stock Connect innovative-drug index rose 1.5%, and Hengrui rose 2.4% in A-shares. Iambic's AI-drug IPO gained 18% on day one, and Recursion's $200M raise was oversubscribed.
- Bitcoin briefly broke below $80,000. About $948M of positions were liquidated in 24 hours, and US spot ETFs saw about $859M of net outflows over six sessions.
By theme
AI
- Google launched Gemini 4 Argon at $2/$10 per million tokens, rising to $4/$20 after 11-30. Flagship rivals are priced at $10/$50. Artificial Analysis scored it 53, level with GPT-6 Astra and Claude Fable 5.1.
- The neoclouds are the epicenter. CoreWeave rebounded 5.9% after Jensen Huang's endorsement, but Oracle, with negative free cash flow, is rated Sell.
- Barclays cut DELL, HPE and NTAP to neutral, saying growth came from memory price pass-through rather than an AI inflection. Dell fell 6.8% and HPE 7.1%.
- Software held up better than hardware: ServiceNow rose 6.1% and AppLovin 6.5%.
Robotics
- Musk said China's magnet export limits delay Optimus by 2–3 months. Figure's Helix-02 ran an 8-hour factory shift without intervention.
- UBTech fell 6.8% on a gap between 13,361 U1 orders and a 2026 delivery target of 1,500–2,000 units.
- Intuitive Surgical reports 10-20 and is a Buy candidate. Tesla is Watch ahead of its 10-21 earnings.
Space
- Rocket Lab pushed Neutron's first flight to 2027, the fourth delay, and fell 6.6%. Its CFO sold about $9.9M of stock on 10-01.
- Google's Suncatcher prototype satellite confirmed TPUs running in orbit. Planet Labs is the platform builder.
- Chinese space stocks fell about 3% despite a successful Zhuque-2 ten-satellite launch.
Biotech
- Danaher announced an "autonomous science" collaboration with Nvidia. Baker lab published two Nature papers on de novo protease design.
- A Wyss Institute study found that SRSF1 overexpression extended median lifespan in mice by 14%.
- Moderna is up 702% year to date and trades at 2.3x the consensus target. The briefing rates it Sell.
Hong Kong, A-shares and crypto
- Hong Kong: the Hang Seng Tech index fell 2.72%, and Lenovo fell 14.5%. Innovative drugs rose.
- A-shares: the Shanghai Composite fell 1.59%, and Innolight and Eoptolink fell 5.2% and 7.5%. SMIC's A-share rose 1.84% while its H-share fell 3.96%, a premium of about 118% by the briefing's approximate FX estimate.
- Crypto: Ether led losses, and Solana open interest rose after the CPI print, which the briefing flags as a risk.
Rating highlights
| Ticker | Company | Call | Why |
|---|---|---|---|
| ORCL:NYSE | Oracle | Sell | Highest-leverage mega-cap AI builder; negative free cash flow and rating-downgrade tail risk. |
| MRNA:NASDAQ | Moderna | Sell | Price is 2.3x consensus target; RSI 72; melanoma data is a binary event. |
| TSM:NYSE | TSMC ADR | Buy | Record Q3, Q4 guidance up 12–16% sequentially; stock sold on liquidity. |
| ASML:NASDAQ | ASML | Buy | Two-year order visibility; supply short through 2027–2028. |
| NVDA:NASDAQ | Nvidia | Buy | Forward PE 13.8; TSMC Q4 guidance cross-validates shipments. |
| LLY:NYSE | Eli Lilly | Buy | Core beneficiary of three-market flow into biotech; earnings 10-29. |
| AVGO:NASDAQ | Broadcom | Hold (downgraded) | Within 0.7% of stop; no adds during seven-day SOX slide. |
| VICR:NASDAQ | Vicor | Watch (downgraded) | Fell 10% through stop; USITC investigation; earnings 10-20. |
| 002050:SZSE | Sanhua Intelligent Controls | Watch (downgraded) | Broke stop; Optimus delay is the direct cause. |
| CRWV:NASDAQ | CoreWeave | Watch | Demand is real, but financing costs are extreme; wait for CDS below 800bp. |
| 0700:HKEX | Tencent | Buy | Forward PE 12.3, little leverage exposure; defend the 409.58 stop. |
| 0981:HKEX | SMIC (H-share) | Hold | Roughly half the A-share price; cheaper entry to Chinese compute. |
| 3692:HKEX | Hansoh Pharmaceutical | Buy | PE 24, profit up 40%, ESMO catalyst; binary data risk. |
| IAM:NASDAQ | Iambic Therapeutics | Watch | Pure AI-drug IPO, but up 18% on a tiny float; no coverage. |
Tenbagger radar
- The briefing contains no ten-bagger radar section. There was no change to the watch pool.
Risks to watch
- Credit: CoreWeave CDS above 1,000bp and Oracle rating risk. The briefing's falsifier for TSMC is CDS above 1,000bp for two weeks plus an Nvidia Q4 shipment cut.
- Earnings: Haiguang, Intuitive Surgical and Vicor on 10-20. Tesla, Meta, Danaher, Thermo Fisher and Lam Research on 10-21. Alphabet, Microsoft and KLA on 10-28. Lilly on 10-29.
- Stops: SPCX, VRT, 9988, NOVT and TSM closed below their stop levels; the briefing says to follow stop discipline. AMAT is 0.4% above its stop.
- Macro: the October FOMC is described as a "coin flip." Bitcoin's $80,000 level, a possible ESMO data disappointment and the Moderna melanoma data are flagged.